drugset / Trial / NCT00671554
Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if treatment with the autologous cellular vaccine, Melaxin, in combination with Bacillus Calmette-Guerin (BCG) injections is effective in Stage IV malignant melanoma.
Timeline
- Start
- 2008-04
- Primary completion
- 2009-02
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melaxin | Cell therapy | 1 ml | Subcutaneous |
| Subject | Melaxin | Cell therapy | 250000 cells | Subcutaneous |
| Background | Bacillus Calmette-Guérin | Vaccine | 1e+06 unknown | Subcutaneous |